Drug maker launches generic spray for psoriasis
A drug maker in the area has launched a generic version of a topical spray for treating psoriasis.
Dublin-based Perrigo — which has its North American headquarters in Allegan — released last month an AB-rated generic version of Topicort (desoximetasone) Topical Spray 0.25 percent.
Topicort Topical Spray is indicated for the treatment of plaque psoriasis in patients 18 or older.
Its annual market sales for the 12 months ending October 2018 were about $18 million as measured by global clinical research and consulting company IQVIA.
“This launch exemplifies Perrigo’s ongoing commitment to developing quality, high-value alternatives in important treatment categories,” said Sharon Kochan, EVP and president of Rx Pharmaceuticals, Perrigo.
“The Rx team continues to leverage our extended topicals strategy and development capabilities to deliver important products to patients.”
Perrigo Company (NYSE: PRGO), a global over-the-counter consumer goods and pharmaceutical company, was founded in Allegan in 1887 as a packager of generic home remedies.
The company makes OTC products and supplies infant formulas and topical medications across a variety of product categories and geographies in North America, Europe and Australia, as well as Israel and China.
The company reported net revenue of $4.9 billion in 2017.